Sign In
Buy TRAW
$1.45
+0.0300 (+2.11%)
At Close: Jun 03, 2026
Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript
01:14pm, Thursday, 14'th Aug 2025
Traws Pharma, Inc. (NASDAQ:TRAW ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
07:00am, Thursday, 14'th Aug 2025
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM)
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
07:00am, Friday, 08'th Aug 2025
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel th
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
06:30am, Monday, 30'th Jun 2025
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
07:00am, Tuesday, 03'rd Jun 2025
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel th
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel the
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
07:00am, Thursday, 15'th May 2025
FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing th
Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript
08:50pm, Tuesday, 01'st Apr 2025
Traws Pharma, Inc. (NASDAQ:TRAW ) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pa
Traws Pharma Announces Management Updates
04:30pm, Friday, 28'th Mar 2025
NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel t
Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird Flu Ratutrelvir, a main
Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR
07:30am, Tuesday, 25'th Mar 2025
NEWTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel t
Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
07:00am, Friday, 21'st Mar 2025
NEWTOWN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel t
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
07:00am, Monday, 03'rd Mar 2025
NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral sm
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
07:00am, Friday, 28'th Feb 2025
NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for th
Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention NEWTOWN, Pa. , Jan. 23, 2025 /PRNewswire/ -- Tr
